Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Trauma and Emergency Surgery
Published in: European Journal of Trauma and Emergency Surgery 1/2022

01-02-2022 | Traumatic Brain Injuries | Original Article

A multi-staged neuropeptide response to traumatic brain injury

Authors: José Luís Alves, João Mendes, Ricardo Leitão, Ana Paula Silva, Anabela Mota Pinto

Published in: European Journal of Trauma and Emergency Surgery | Issue 1/2022

Login to get access

Abstract

Purpose

As the most abundant neuropeptides in Central Nervous System, Substance P and Neuropeptide Y are arguably involved in the response to brain trauma. This study aims to characterize a new concept of multi-staged neuropeptide response to TBI.

Methods

This study assessed Substance P, Neuropeptide Y, S100B, standard inflammatory parameters and ionic disturbance in TBI victims, with and without intracranial lesions, and healthy controls. In the group with intracranial lesions, blood samples were drawn until 6 h after initial trauma, at 48 h and 7 days post-TBI.

Results

An early increase in Substance P (mean 613.463 ± 49.055 SE 6 h post-TBI with brain contusions vs. 441.441 ± 22.572 SE pg/dL control group) is evident. Concerning TBI without intraparenchymatous lesions, an increase in substance P is also present (825.60 ± 23.690 SE pg/dL). Following an initial increase and subsequent fall in NPY levels (45.997 ± 4.96 SE 6 h post-TBI vs. 32.395 ± 4.056 SE 48 h post-TBI vs. 19.700 ± 1.462 SE pg/mL control group), a late increase in NPY is obvious (43.268 ± 6.260 SE pg/mL 7 day post-TBI). Post-traumatic hypomagnesemia (0.754 ± 0.015 SE 6 h post-TBI vs. 0.897 ± 0.021 SE mmol/L control group) and a peak in S100B (95.668 ± 14.102 SE 6 h post-TBI vs. 30.187 ± 3.347 SE pg/mL control group) are also present.

Conclusion

A multi-staged neuropeptide response to TBI is obvious and represents a potential therapeutic strategy for the treatment of intraparenchymal lesions and cerebral edema following TBI.
Literature
1.
Fu T, Jing R, McFaull S, Cusimano M. Health & economic burden of traumatic brain injury in the emergency department. Can J Neurol Sci. 2016;43(2):238–47.PubMed
2.
Humphreys I, Wood R, Phillips C, Macey S. The costs of traumatic brain injury: a literature review. Clin Outcomes Res. 2013;26(5):281–7.
3.
Sorby-Adams AJ, Marcoionni AM, Dempsey ER, Woenig JA, Turner RJ. The role of neurogenic inflammation in blood-brain disruption and development of cerebral oedema following acute central nervous system injury. Int J Mol Sci. 2017;18(8).
4.
5.
Shandra O, Winemiller A, Heithoff B, et al. Repetitive diffuse mild traumatic brain injury causes an atypical astrocyte response and spontaneous recurrent seizures. J Neurosci. 2019;39(10):1944–63.PubMedPubMedCentral
6.
Dobrachinski F, Gerbatin R, Sartori G, et al. Regulation of mitochondrial function and glutamatergic system are the target of guanosine effect in traumatic brain injury. J Neurotrauma. 2017;34(7):1318–28.PubMed
7.
Djordevic J, Sabbir MG, Albensi BC. Traumatic brain injury as a risk factor for alzheimer’s disease: is inflammatory signaling a key player? Curr Alzheimer Res. 2016;13(7):730–8.
8.
Mouzon B, Chaytow H, Crynen G, et al. Repetitive mild traumatic brain injury in a mouse model produces learning and memory deficits accompanied by histological changes. J Neurotrauma. 2012;29(18):2761–73.PubMed
9.
Croall I, Smith FE, Blamire AM. Magnetic resonance spectroscopy for traumatic brain injury. Top Magn Reson Imaging. 2015;24(5):267–74.PubMed
10.
Stovell MG, Yan JL, Sleigh A, et al. Assessing metabolism and injury in acute human traumatic brain injury with magnetic resonance spectroscopy: current and future applications. Front Neurol. 2017;12(8):426.
11.
Hoffman JR, Zuckerman A, Ram O, et al. Behavioral and inflammatory response in animals exposed to a low-pressure blast wave and supplemented with B-alanine. Aminoacids. 2017;49(5):871–86.
12.
Prakash R, Carmichael ST. Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. Curr Opin Neurol. 2015;28:556–64.PubMedPubMedCentral
13.
Minkkinen M, Iverson GL, Kotilainen AK, et al. Prospective validation of the scandinavian guidelines for initial management of minimal, mild, and moderate head injuries in adults. J Neurotrauma. 2019;36(20):2904–12.PubMed
14.
Lorente L, Martín M, Almeida T, et al. Serum substance P levels are associated with severity and mortality in patients with severe traumatic brain injury. Crit Care. 2015;19:192.PubMedPubMedCentral
15.
Vink R, Den Heuvel C. Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics. 2010;7(1):74–80.PubMedPubMedCentral
16.
Lukacs M, Tajti J, Fulop F, Toldi J, Edvinsson L, Vecsei L. Migraine, neurogenic ınflammation, drug development - pharmacochemical aspects. Curr Med Chem. 2017;24(33):3649–65.PubMed
17.
Suvas S. Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J Immunol. 2017;199(5):1543–52.PubMed
18.
19.
Vink R, Gabrielian L, Thornton E. The role of substance P in secondary pathophysiology after traumatic brain injury. Front Neurol. 2017;8:304.PubMedPubMedCentral
20.
Corrigan F, Mander KA, Leonard AV, Vink R. Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation. J Neuroinflamm. 2016;13(1):264.
21.
Zhe Z, Hongyuan B, Wenjuan Q, Peng W, Xiaowei L, Yan G. Blockade of glutamate receptor ameliorates lipopolysaccharide-induced sepsis through regulation of neuropeptides. Biosci Rep. 2018;8(38):3.
22.
Ameliorate JL, Ghabriel MN, Vink R. Magnesium enhances the beneficial effects of NK1 antagonist administration on blood-brain barrier permeability and motor outcome after traumatic brain injury. Magnes Res. 2017;30(3):88–97.PubMed
23.
Ramamoorthy P, Wang Q, Whim M. Cell type-dependent trafficking of neuropeptide Y-containing dense core granules in CNS neurons. J Neurosci. 2011;31(41):14783–8.PubMedPubMedCentral
24.
Lynds R, Lyu C, Lyu GW, et al. Neuronal plasticity of trigeminal ganglia in mice following nerve injury. J Pain Res. 2017;9(10):349–57.
25.
Silva AP, Xapelli S, Pinheiro PS, et al. Up-regulation of neuropeptide Y levels and modulation of glutamate release through neuropeptide Y receptors in the hippocampus of kainate-induced epileptic rats. J Neurochem. 2005;93(1):163–70.PubMed
26.
Decressac M, Prestoz L, Veran J, Cantereau A, Jaber M, Gaillard A. Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiol Dis. 2009;34(3):441–9.PubMed
27.
Geloso MC, Corvino V, Di Maria V, Marchese E, Michetti F. Cellular targets for neuropeptide Y-mediated control of adult neurogenesis. Front Cell Neurosci. 2015;16(9):85.
28.
Spencer B, Potkar R, Metcalf J, et al. Systemic Central Nervous System (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of Alzheimer disease. J Biol Chem. 2016;291(4):1905–20.PubMed
29.
Zhang Z, Ma Z, Zou W, Guo H, Liu M, Ma Y. The appropriate marker for astrocytes: comparing the distribution and expression of three astrocytic markers in different mouse cerebral regions. Biomed Res Int. 2019;24:9605265.
30.
Thelin E, Nimer F, Frostell A, et al. A serum protein biomarker panel improves outcome prediction in human traumatic brain injury. J Neurotrauma. 2019;36(20):2850–62.PubMedPubMedCentral
31.
Frankel M, Fan L, Yeatts SD, et al. Association of very early serum levels of S100B, glial fibrillary acidic protein, ubiquitin C-terminal hydroxilase-L1 and spectrin breakdown roduct with outcome in proTECT III. J Neurotrauma. 2019;36(20):2863–71.PubMedPubMedCentral
32.
33.
Thelin E, Nelson D, Bellander BM. A review of the clinical utility of sérum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochirur. 2017;159:209–25.
34.
Lim L, Ho RM, Ho C. Dangers of mixed martial arts in the development of chronic traumatic encephalopathy. Int J Environ Res Public Health. 2019;16(2):254.PubMedCentral
35.
Donkin JJ, Cernak I, Blumbergs PC, Vink R. A substance P antagonist reduces axonal injury and improves neurologic outcome when administered up to 12 h after traumatic brain injury. J Neurotrauma. 2011;28:217–24.PubMed
36.
Park M, Oh H, Ko I, et al. Influence of mild traumatic brain injury during pediatric stage on short-term memory and hippocampal apoptosis in adult rats. J Exerc Rehabil. 2014;10(3):148–54.PubMedPubMedCentral
37.
Hellewell S, Semple B, Morganti-Kossmann M. Therapies negating neuroinflammation after brain trauma. Brain Res. 2016;1640:36–56.PubMed
38.
Dikranian K, Cohen R, Macdonald C, et al. Mild traumatic brain injury to the infant mouse causes robust white matter axonal degeneration which precedes apoptotic death of cortical and thalamic neurons. Exp Neurol. 2008;211(2):551–60.PubMedPubMedCentral
39.
Ercole A, Thelin EP, Holst A, Bellander BM, Nelson D. Kinetic modelling of sérum S100B after traumatic brain injury. BMC Neurol. 2016;16:93.PubMedPubMedCentral
40.
Leonard AV, Manavis J, Blumbergs PC, Vink R. Changes in substance P and NK1 receptor immunohistochemistry following human spinal cord injury. Spinal Cord. 2014;52(1):17–23.PubMed
41.
Giancarelli A, Birrer KL, Alban RF, Hobbs BP, Liu-deRyke X. Hypocalcemia in trauma patients receiving massive transfusion. J Surg Res. 2016;202(1):182–7.PubMed
42.
Naghibi T, Mohajeri M, Dobakhti F. Inflammation and outcome in traumatic brain injury: does gender effect on survival and prognosis? J Clin Diagn Res. 2017;11(2):6–9.
43.
Alves JL, Rato J, Silva V. Why does brain trauma research fail? World Neurosurg. 2019;130:115–21.PubMed
44.
Sabban F, Vink R, Turner RJ. Inflammation in acute CNS injury: a focus on the role of substance P. Br J Pharmacol. 2016;173:703–15.
45.
Zhang L, Bijker MS, Herzog H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and câncer. Pharmacol Ther. 2011;131(1):91–113.PubMed
46.
Sabban EL, Laukova M, Alaluf LG, Olsson E, Serova LI. Locus coeruleus response to single-prolonged stress and early intervention with intranasal neuropeptide Y. J Neurochem. 2015;135(5):975–86.PubMed
47.
48.
Morin LP. Neuroanatomy of the extended circadian rhythm system. Exp Neurol. 2013;243:4–20.PubMed
49.
Morosawa S, Iritani S, Fujishiro H, et al. Neuropeptide Y neuronal network dysfunction in the frontal lobe of a genetic mouse model of schizophrenia. Neuropeptides. 2017;62:27–35.PubMed
50.
Angelucci F, Gelfo F, Fiore M, et al. The effect of neuropeptide Y on cell survival and neurotrophin expression in in-vitro models of Alzheimer’s disease. Can J Physiol Pharmacol. 2014;92(8):621–30.PubMed
51.
Markaki E, Ellul J, Kefalopoulou Z, et al. The role of ghrelin, neuropeptide Y and leptin peptides in weight gain after deep brain stimulation for Parkinson’s disease. Stereotact Funct Neurosurg. 2012;90(2):104–12.PubMed
52.
Uckermann O, Wolf A, Franziska K, Wiedemann P, Reichenbach A, Bringmann A. Neuropeptide Y inhibits hypotonic glial cell swelling in the postischemic rat retina via glutamatergic Neuron-to-Glia Signaling. Invest Ophtalmol Vis Sci. 2005;46:2224.
53.
Sampaolo S, Liguori G, Vittoria A, et al. First study on the peptidergic innervation of the brain superior sagittal sinus in humans. Neuropeptides. 2017;65:45–55.PubMed
54.
Edyvane KA, Smet PJ, Trussell DC, Jonavicius J. Patterns of neuronal colocalisation of tyrosine hydroxylase, neuropeptide Y, vasoactive intestinal polypeptide, calcitonin gene-related peptide and substance P in human uréter. J Auton Nerv Syst. 1994;48(3):241–55.PubMed
55.
Nelson TS, Fu W, Donahue RR, et al. Facilitation of neuropathic pain by the NPY Y1 receptor-expressing subpopulation of excitatory interneurons in the dorsal horn. Sci Rep. 2019;10(9):7248.
56.
57.
He XY, Dan QQ, Wang F, et al. Protein network analysis of the serum and their functional implication in patients subjected to traumatic brain injury. Front Neurosci. 2019;12:1049.PubMedPubMedCentral
58.
McIntosh TK, Ferriero D. Changes in neuropeptide Y after experimental traumatic brain injury in the rat. J Cereb Blood Flow Metab. 1992;12(4):697–702.PubMed
59.
Sun Z, Liu S, Kharmalov EA, Miler ER, Kelly KM. Hippocampal neuropeptide Y protein expression following controlled cortical impact and posttraumatic epilepsy. Epilepsy Behav. 2018;87:188–94.PubMed
60.
Chiodera P, Volpi R, Pilla S, Cataldo S, Coiro V. Decline in circulating neuropeptide Y levels in normal elderly human subjects. Eur J Endocrinol. 2000;143:715–6.PubMed
61.
Johnson V, Stewart J, Begbie F, Trojanowski J, Smith D, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013;136(1):28–422.PubMedPubMedCentral
62.
Fatoba O, Kloster E, Saft C, Gold R, Arning L, Ellrichmann G. L22 intranasal application of NPY and NPY13–36 ameliorate disease pathology in R6/2 mouse model of huntington’s disease. J Neurol Neurosurg Psychiatry. 2016;87:A97–A9898.
63.
Sabban EL, Serova LI. Potential of intranasal neuropeptide Y (NPY) and/or melanocortin 4 receptor (MC4R) antagonists for preventing or treating PTSD. Mil Med. 2018;183(suppl1):408–12.PubMed
64.
Campbell D, Raftery N, Tustin R, et al. Measurement of plasma-derived substance P: biological, methodological, and statistical considerations. Clin Vaccine Immunol. 2006;13(11):1197–203.PubMedPubMedCentral
65.
Corbally N, Powell D, Tipton KF. The binding of endogenous and exogenous substance-P in human plasma. Biochem Pharmacol. 1990;39:1161–6.PubMed
66.
Szczygielski J, Glameanu C, Müller A, et al. Changes in posttraumatic brain edema in craniectomy-selective brain hypothermia model are associated with modulation of aquaporin-4 level. Front Neurol. 2018;9:799.PubMedPubMedCentral
Metadata
Title
A multi-staged neuropeptide response to traumatic brain injury
Authors
José Luís Alves
João Mendes
Ricardo Leitão
Ana Paula Silva
Anabela Mota Pinto
Publication date
01-02-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Trauma and Emergency Surgery / Issue 1/2022
Print ISSN: 1863-9933
Electronic ISSN: 1863-9941
DOI
https://doi.org/10.1007/s00068-020-01431-z

Other articles of this Issue 1/2022

European Journal of Trauma and Emergency Surgery 1/2022 Go to the issue

Original Article

Trauma patients with human immunodeficiency virus (HIV): a propensity matched analysis

Original Article

Association between mortality and frailty in emergency general surgery: a systematic review and meta-analysis

Original Article

Effects of diaphragm thickness on rehabilitation outcomes in post-ICU patients with spinal cord and brain injury

Original Article

Changes in transfusion and fluid therapy practices in severely injured children: an analysis of 5118 children from the TraumaRegister DGU®

Original Article

Increased hospital treatment volume of splenic injury predicts higher rates of successful non-operative management and reduces hospital length of stay: a Swiss Trauma Registry analysis

Original Article

Investigation of the relationship of the number, localization, and displacement of rib fractures with intrathoracic structures and abdominal solid organ complications using computed tomography